Resultados da pesquisa - Jaume Capdevila

Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe Por Rossella Elisei, Enrique Grande, Michael C. Kreissl, Sophie Leboulleux, Tarun Puri, Nicolas Fasnacht, Jaume Capdevila

Obter o texto integral

Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor Por Jesús Yaringaño, Jorge Hernando, Jorge Hernando, Alejandro García-Álvarez, Alejandro García-Álvarez, Carmela Iglesias-Felip, Carles Zafón, Ana Vivancos, María Roca-Herrera, Sergio Pérez-Fernández, Sergio Pérez-Fernández, Sandra Martínez-Badal, Sandra Martínez-Badal, Belén Elguero, Belén Elguero, Jaume Capdevila, Jaume Capdevila

Obter o texto integral

Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subc... Por Simron Singh, Diego Ferone, Jaume Capdevila, Jennifer Ang Chan, Wouter W. de Herder, Daniel Halperin, Josh Mailman, Lisa Hellström, Hanna Liedman, Agneta Svedberg, Fredrik Tiberg

Obter o texto integral

Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous dep... Por Simron Singh, Diego Ferone, Jaume Capdevila, Jennifer Ang Chan, Wouter W. de Herder, Daniel Halperin, Josh Mailman, Lisa Hellström, Hanna Liedman, Agneta Svedberg, Fredrik Tiberg

Obter o texto integral

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice Por Jaume Capdevila, Desiree’ Deandreis, Cosimo Durante, Sophie Leboulleux, Markus Luster, Romana Netea-Maier, Kate Newbold, Susanne Singer, Gerasimos P Sykiotis, Beate Bartes, Kate Farnell, Laura Deborah Locati

Obter o texto integral

Molecular predictive biomarker testing in advanced thyroid cancer – a European consensus Por Aleš Ryška, Jaume Capdevila, Matthias S Dettmer, Rossella Elisei, Dagmar Führer, Julien Hadoux, Barbara Jarząb, Laura D Locati, Kate Newbold, Giovanni Tallini, Silvia Uccella, Lori Wirth, Ravinder Singh, Iris M Simon, Pilar Camacho, Laura Fugazzola

Obter o texto integral

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-3... Por Marcia S. Brose, Bhumsuk Keam, Jolanta Krajewska, Ana O. Hoff, Fernanda Vaisman, Chia-Chi Lin, Erika Hitre, Daniel W. Bowles, Bruce Robinson, Steven I. Sherman, Nuttapong Ngamphaiboon, Xiang Guo, Andrew Simmons, Denise Williamson, Svetlana Andrianova, Nicholas Berry, Jaume Capdevila

Obter o texto integral

A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer Por Maria Balaguer-Montero, Adrià Marcos Morales, Marta Ligero, Christina Zatse, David Leiva, Luz M. Atlagich, Nikolaos Staikoglou, Cristina Viaplana, Camilo Monreal, Joaquin Mateo, Jorge Hernando, Alejandro García-Álvarez, Francesc Salvà, Jaume Capdevila, Elena Elez, Rodrigo Dienstmann, Elena Garralda, Raquel Perez-Lopez

Obter o texto integral

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II st... Por Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, Patrick Schöffski, Yann Godbert, Patrice Rodien, Barbara Jarzab, Domenico Salvatore, Sylvie Zanetta, Jaume Capdevila, Lars Bastholt, Christelle De La Fouchardiere, Yassine Lalami, Stéphane Bardet, Frank Cornélis, Marek Dedecjus, Thera Links, Ward Sents, Martin Schlumberger, D. Laura Locati, Katie Newbold

Obter o texto integral

DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype Por Estefania Cuesta-Borràs, Cándida Salvans, Oriol Arqués, Irene Chicote, Lorena Ramírez, Laia Cabellos, Jordi Martínez-Quintanilla, Alex Mur-Espinosa, Alejandro García-Álvarez, Jorge Hernando, Juan Ramón Tejedor, Oriol Mirallas, Elena Élez, Mario F. Fraga, Josep Tabernero, Paolo Nuciforo, Jaume Capdevila, Héctor G. Palmer, Isabel Puig

Obter o texto integral

Impact of the COVID-19 pandemic in the early-onset colorectal cancer Por Iosune Baraibar, Ariadna García, Francesc Salvà, Javier Ros, Nadia Saoudi, Raquel Comas, Gloria Castillo, Mireia Sanchis, Alejandro García-Álvarez, Jorge Hernando, Jaume Capdevila, Marta R Castells, Marc Martí, Stefania Landolfi, Eloy Espín, Begoña Navalpotro, Jorge Guevara, Cristina Dopazo, Paolo Nuciforo, Ana Vivancos, Josep Tabernero, Elena Élez

Obter o texto integral

VITAL phase 2 study: Upfront 5‐fluorouracil, mitomycin‐C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09‐02) Por Jaime Feliu, Rocio Garcia‐Carbonero, Jaume Capdevila, Inmaculada Guasch, Vicente Alonso‐Orduna, Carlos Lopez, Pilar Garcia‐Alfonso, Carmen Castanon, Isabel Sevilla, Laura Cerezo, Carles Conill, Begona Quintana‐Angel, Maria E. Sanchez, Ismael Ghanem, Marta Martin‐Richard, Miriam Lopez‐Gomez, Ana Leon, Monica Caro, Teresa Fernandez, Joan Maurel

Obter o texto integral

Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter... Por Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso, Paula Jimenez-Fonseca, Alex Teule, Enrique Grande, Isabel Sevilla, Marta Benavent, Teresa Alonso-Gordoa, Ana Custodio, Beatriz Anton-Pascual, Jorge Hernando, Eduardo Polo, Oscar Alfredo Castillo-Trujillo, Arantza Lamas-Paz, Ana Teijo, Yolanda Rodriguez-Gil, Beatriz Soldevilla, Rocio Garcia-Carbonero

Obter o texto integral

630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study Por Salvatore Grisanti, Vivek Subbiah, Eric Baudin, Gedske Daugaard, Alfredo Berruti, Jennifer Martinez, Camilo Jimenez, Harm Haak, Jerome Kervevan, Lucie Aubergeon, Chloé Ventujol, Christophe Bonny, Laurent Chene, Joao Gamelas Magalhaes, CWillemien Menke-vander Houven van Oordt, Martin Fassnacht, Jaume Capdevila, Christelle de la Fouchardière, Dan Granberg, Matthias Kroiss, Hélène Toussaint, Camille Belyn, Jean-Michel Paillarse

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial Por Jaume Capdevila, Jorge Hernando, Javier Molina-Cerillo, Maria Plana Serrahima, Miren Taberna Sanz, Beatriz Castelo, Cristina Álvarez-Escolá, Alberto Carmona-Bayonas, Inmaculada Ballester Navarro, Lara Iglesias, Mateo Bover, Alejandro Garcia-Alvarez, Javier Lavernia, Ricardo Yayá Tur, Sofia Ruiz, Neus Baste, Isabel Lorenzo-Lorenzo, Alfredo Sanchez-Hernandez, Enrique Sanz-Garcia, Gloria Marquina, Paolo Nuciforo, Belén Elguero, Enrique Grande, Teresa Alonso-Gordoa

Obter o texto integral

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumor... Por Jaume Capdevila, Virginia Pubul, Urbano Anido, Thomas Walter, Javier Molina‑Cerrillo, Teresa Alonso‑Gordoa, Rocio Garcia‑Carbonero, Maria San‑Roman‑Gil, Belen Llana, Paula Jimenez‑Fonseca, Marta Benavent Viñuales, Catherine Ansquer, Eric Baudin, Come Lepage, Maribel del Olmo‑García, José Carlos Ruffinelli, Amandine Beron, Magalie Haissaguerre, Emmanuel Deshayes, David Taïeb, Sergio Baldari, Maddalena Sansovini, Sara Cingarlini, Angelina Filice, Francesco Panzuto, Rosa Álvarez‑Álvarez, Laurence Lousberg, Frank Aboubakar Nana, Jorge Hernando, Alejando García‑Álvarez, Amparo García‑Burillo, Guillermo Villacampa, Timon Vandamme, Nicola Fazio, Alice Durand

Obter o texto integral

A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lun... Por Jaume Capdevila, Virginia Pubul, Urbano Anido, Thomas Walter, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Rocio Garcia-Carbonero, Maria San-Roman-Gil, Belen Llana, Paula Jimenez-Fonseca, Marta Benavent Viñuales, Catherine Ansquer, Eric Baudin, Come Lepage, Maribel del Olmo-García, José Carlos Ruffinelli, Amandine Beron, Magalie Haissaguerre, Emmanuel Deshayes, David Taïeb, Sergio Baldari, Maddalena Sansovini, Sara Cingarlini, Angelina Filice, Francesco Panzuto, Rosa Álvarez-Álvarez, Laurence Lousberg, Frank Aboubakar Nana, Jorge Hernando, Alejando García-Álvarez, Amparo García-Burillo, Guillermo Villacampa, Timon Vandamme, Nicola Fazio, Alice Durand

Obter o texto integral

A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study Por Maria Argente-Pla, Maria Argente-Pla, Maria Argente-Pla, Miguel Antonio Sampedro-Nuñez, Rocio Garcia-Carbonero, Ana Custodio, Jorge Hernando, Lorena Suarez, Lorena Hernandez-Rienda, Lorena Hernandez-Rienda, Lorena Hernandez-Rienda, Inmaculada Peiró, Inmaculada Peiró, Vicente Alonso, Raquel Serrano, Nuria Valdés, Marcos Melian, Beatriz Febrero, Josefina Biarnes, José Ángel Díaz-Pérez, Javier Molina-Cerrillo, Carlos Lopez, Miguel Ángel Martínez Olmos, Miguel Ángel Martínez Olmos, Miguel Ángel Martínez Olmos, Juan Francisco Merino-Torres, Juan Francisco Merino-Torres, Juan Francisco Merino-Torres, Jaume Capdevila, Maribel del Olmo-García, Maribel del Olmo-García, Maribel del Olmo-García, NUTRIGETNE GROUP

Obter o texto integral